This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: We agree with Drs Weinberg, Luque, and Brown that efavirenz is not an optimal choice for nonoccupational HIV NPEP in women who are or may become pregnant. Unfortunately for clinicians’ decision-making, data are limited on the relative efficacy of any HIV NPEP regimen. This limitation forces clinicians to choose regimens based on the best available evidence that can be extracted from studies involving persons already infected with HIV, as well as from mother-to-child HIV transmission prevention studies, basic science research, and HIV NPEP investigations that are not randomized, controlled trials. For example, Schechter et al¹ educated a cohort of men who had sex with men to take zidovudine/lamivudine for NPEP after high-risk exposures and demonstrated a lower incidence of HIV seroconversion compared with those who did not take HIV NPEP; however, the trial did not include other HIV NPEP regimens. As a result, this study provides additional . . . [Full Text of this Article]

Kenneth H. Mayer, MD
Department of Medicine

Roland C. Merchant, MD, MPH
rmerchant@lifespan.org
Department of Emergency Medicine
Brown Medical School
Providence, RI

RELATED ARTICLES

Nonoccupational HIV Postexposure Prophylaxis
Geoffrey A. Weinberg, Amneris E. Luque, and Sheldon T. Brown
JAMA. 2005;294(13):1615.
EXTRACT | FULL TEXT  

Perspectives on New Recommendations for Nonoccupational HIV Postexposure Prophylaxis
Roland C. Merchant and Kenneth H. Mayer
JAMA. 2005;293(19):2407-2409.
EXTRACT | FULL TEXT